Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Hyqvia Market CAGR Outlook And Future Development
Historic growth stemmed from the limitations inherent in intravenous ig therapy, the elevated infection risk observed in pi patients, the prompt adoption of sc immunoglobulins, the imperative for an improved quality of life, and the ongoing expansion within immunology specialty care.
Anticipated growth during the projection period stems from a surge in primary immunodeficiency diagnoses, the proliferation of home healthcare provisions, enhanced management of pediatric primary immunodeficiency, a growing preference for extended-interval dosing regimens, and the expanding reach of specialty pharmacy networks.
Prominent trends identified for the projected period involve a move towards less frequent immunoglobulin administration, increasing uptake of at-home infusion treatments, a heightened demand for combined immunotherapy solutions, greater patient convenience in primary immunodeficiency therapy, and the broader application of subcutaneous immunoglobulins.
Get A Free Sample Report With In-Depth Market Insights:
Hyqvia Market Development Factors: What’s Supporting Demand?
The increasing occurrence of autoimmune diseases is projected to propel the expansion of the hyqvia market. These conditions involve the immune system erroneously targeting healthy cells, tissues, or organs, resulting in inflammation and impaired function. The rise in autoimmune diseases stems from various factors, such as genetic tendencies, environmental stimuli, dietary shifts, greater exposure to pollutants, and enhanced diagnostic capabilities. Hyqvia is employed for autoimmune diseases because it provides immunoglobulin therapy, which modulates the immune system and reduces abnormal responses that attack the body’s own tissues. For example, in May 2023, a study by the NIHR Imperial Biomedical Research Centre, a UK-based government research institute and agency, examined anonymized electronic health records from 22 million UK individuals. This research focused on 19 prevalent autoimmune diseases, affecting approximately 10% of the population, with 13% of women and 7% of men impacted. Consequently, the rising prevalence of autoimmune diseases is fostering growth in the hyqvia market.
Hyqvia Market Segment Landscape: Which Areas Lead Development?
The hyqvia market covered in this report is segmented –
1) By Patient Demographics: Pediatric Patients, Adult Patients
2) By Distribution Channel: Hospitals, Specialty Pharmacies, Home Healthcare Providers, Retail Pharmacies
3) By Application: Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy, Other Applications
Hyqvia Market Transformation Trends: What Innovations Are Driving Change?
A significant trend within the hyqvia market involves a focus on developing innovative products, such as immune globulin infusion, intended for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and primary immunodeficiency (PI). Immune globulin infusion is a therapeutic approach that delivers antibody-rich plasma proteins to address immune system deficiencies and autoimmune conditions. For instance, in January 2024, Takeda Pharmaceutical Company Ltd., a Japan-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had granted approval for its product, HYQVIA® (immune globulin infusion 10% [human] with recombinant human hyaluronidase), to be used as a maintenance therapy for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). This FDA approval authorizes HYQVIA for preventing relapses of neuromuscular disability and impairment caused by CIDP, a rare neuromuscular disorder affecting approximately five to seven individuals per 100,000 in the U.S.
Hyqvia Market Industry Leaders And Competitive Landscape
Major companies operating in the hyqvia market are Takeda Pharmaceutical Company Limited
View The Full Hyqvia Market Report:
Hyqvia Market Geographic Distribution And Regional Opportunities
North America was the largest region in the hyqvia market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the hyqvia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
